The groundbreaking success of Sildenafil undeniably reshaped the drug landscape, but placing funds in companies heavily reliant on unbranded versions presents a complex picture. While early returns were impressive, the cessation of patents and the rise of cheaper alternatives have diminished sales. Therefore, a thorough analysis of present revenue